On February 12, the artificial intelligence “COVID-19 AI self-test robot” was launched in the learning power. When users have relevant discomfort symptoms and fall into the dilemma of not seeing a doctor for fear of delaying their condition and worrying about cross infection when going out for medical treatment, the initial self-test with AI self-test robot becomes the best choice.

COVID-19 AI self testing robot

Since the Ministry of industry and information technology released the proposal on giving full play to the enabling effect of artificial intelligence to jointly fight against the pneumonia epidemic infected by novel coronavirus on February 4, more and more artificial intelligence enterprises have taken actions to try to get involved in AI assisted diagnosis, AI drug research and development, AI services and other fields. When AI enters the anti epidemic echelon and rigid demand superimposes technological progress, relevant subdivided fields are expected to enter the “fast lane” of development.

“The challenge of the COVID-19 has accelerated the breakthrough of domestic service robot scene application cases. In the future, it is expected to accelerate the popularization of service robots and strengthen the confidence of investment institutions in medical robots, thus contributing to the in-depth development of relevant enterprises.” Wang Wei, Secretary General of the Organizing Committee of China robot summit, said in an interview with reporters.

AI service robot will welcome the golden period

Shanghai Ti Mi Robot Technology Co., Ltd., represented by disinfection robots, invested products in isolation wards, ICUs, operating rooms and fever clinics in hospitals in Wuhan and Shanghai for the first time. The meal delivery robots that have been popular for many years have transformed in the application of developing the field of medical service distribution, and service robots such as nursing, inquiry and tracking are also developing rapidly in the fight against the epidemic.

In fact, in recent years, with the accelerated trend of population aging and the continued strong demand for medical treatment and education, the sales of service robots are growing continuously. According to the 2019 world robot report released by the International Federation of robots, the proportion of service robots in the sales share of all robots has been close to one-third of the whole market. In the field of service robots, the sales growth of logistics system service robots is the most obvious, followed by medical robots.

Some insiders believe that the strong development momentum of service robots, coupled with the market demand generated by the epidemic, will usher in a golden period of development.

“It should be noted that the next big development space of service robots lies in the intelligent judgment and adaptability to complex scenes. At present, service robots can only replace the simple process work of medical personnel. In the future, artificial intelligence technology will realize the ability of robot brain to have more big data and realize autonomous learning. It is very important to complete the transformation from auxiliary to alternative medical diagnosis of medical personnel, so as to solve the uneven distribution of medical resources The status quo of the market. ” Wang Wei told reporters.

Liu Hong, director of the scientific research department of the Shenzhen Research Institute of Peking University, also proposed that the service robot requires not only autonomy and functionality, but also safety and friendliness. In the future, it also needs to truly understand users.

The prospect of AI assisted imaging diagnosis is promising

Recently, the school of telecommunications, Huazhong University of science and technology, in conjunction with Huawei cloud and other teams, developed and launched the COVID-19 AI assisted medical image quantitative analysis system. The system can greatly improve the diagnostic efficiency and help reduce the heavy load of doctors.

Baixiang, the head of the laboratory and professor of Huazhong University of science and technology, said that in combination with clinical information, the system can help doctors more effectively distinguish the early, progressive and severe stages of COVID-19, which is conducive to early screening, prevention and control. At the same time, for the confirmed patients, based on the quantitative analysis of the image data reviewed many times, doctors can effectively evaluate the progress of the disease and the efficacy of medication.

The forecast data from IDC shows that the amount of medical data will reach 40 trillion GB in 2020, and the speed of data generation and sharing will grow rapidly, of which more than 80% of the data is unstructured data. In the face of such a rapidly growing amount of medical data, it is difficult to identify and process without the help of computer intelligent computing. Introducing AI to assist or even replace manual for some routine pathological diagnosis and cancer screening can effectively make up for the problems of low efficiency of manual diagnosis, insufficient pathologists and lack of unified quality control management.

At present, there are a large number of enterprises involved in the AI image-assisted diagnosis market in China, showing a pattern of contention among a hundred schools of thought. According to the reporter, in recent years, technology giants such as Tencent, Alibaba and iFLYTEK have long-term layout and investment in basic artificial intelligence technology. Relying on the advantages of technology, capital and talents, they have accelerated the layout of image AI assisted diagnosis market; With the advantages of channels and hardware, GPS, Lianying and other medical device giants actively expand the field of artificial intelligence and seek new profit growth points for enterprises; In addition, a large number of start-ups have flourished with the popularity of capital by virtue of the flexibility and innovation of their business models.

There are also views that the leading enterprises in the industry have not yet appeared at this stage, and the enterprises that can find a more suitable business model and quickly occupy the market in the future will be in a leading position in the industry.

AI technology becomes a breakthrough point in new drug research and development

During the epidemic, the proposal issued by the Ministry of industry and information technology called on relevant units to optimize AI algorithms and computing power, and help tackle key drug research and development problems such as virus gene sequencing, vaccine / drug research and development, protein screening and so on.

Compared with the traditional model, AI + drug R & D has obvious advantages in time and cost. The deep learning and processing of AI technology can provide convenience for researchers to conduct data analysis, quickly screen literature and corresponding testing.

According to the data report of globalmarketinsight, in the global artificial intelligence medical market, the drug research and development segment accounts for the largest share, about 35%.

According to the reporter, there is still a large gap between China’s drug research and development and the international top level, so it is very difficult to catch up. The development of artificial intelligence has brought opportunities to shorten the gap in new drug research and development in China. At present, domestic enterprises such as Jingtai technology, zero krypton technology and Zhiyao technology have made layout and attracted a lot of capital.

In addition to scientific research teams and pharmaceutical companies, some technology giants are also actively entering the artificial intelligence medical market. At present, Alibaba cloud announced that it will open all AI computing power to public research institutions around the world free of charge to accelerate the research and development of new pneumonia drugs and vaccines. Baidu has set up a special fund for tackling the epidemic and public health security with a total scale of 300 million yuan, and provided artificial intelligence technical support, supporting 100 million computing resources to help disease control institutions, scientific research institutes and other research institutions speed up vaccine research and development.

“In the area of drug innovation, everyone is working hard, but it is far from enough. On the path of artificial intelligence to help us find new drugs, we may still face many challenges, such as how to combine the data of various pharmaceutical companies and use more high-quality data to make better models.” Lai Lipeng, co-founder of Jingtai technology, suggested.

Leave a Reply

Your email address will not be published. Required fields are marked *